Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Rhizen Pharmaceuticals SA
University of California, San Francisco
Celgene
Fondazione Italiana Linfomi - ETS
National Cancer Institute (NCI)
M.D. Anderson Cancer Center